Company intelligence
Solaris Endovascular
Advancing Innovative Vascular Solutions
About Solaris Endovascular
Solaris Endovascular, Inc. is a growth stage US-based medical device company developing advanced endovascular solutions for patients suffering from dialysis access challenges and Peripheral Artery Disease. With a proven stent platform and innovative drug-eluting technology, led by seasoned executives with extensive experience in cardiovascular MedTech, Solaris Endovascular is uniquely positioned and committed to improving long-term patient outcomes and transforming vascular health.
Verified activity
Signals from Solaris Endovascular
4 published signals
Research & Knowledge
Solaris Endovascular announced 92.7% target lesion primary patency at six months with investigational Solaris DE in the DEScover Phase II study presented at CIRSE 2026.
Reported by Solaris Endovascular
Research & Knowledge
Solaris Endovascular announced that Dr. Leonardo Harduin published a clinical study titled DEScover, with 12-month results expected to come next year.
Reported by Randy Hubbell
Presence & Recognition
Solaris Endovascular will present the complete 6-month primary endpoint results from the DEScover Phase II study evaluating the Solaris DE drug-eluting covered stent in hemodialysis patients at CIRSE 2026 in Copenhagen.
Reported by Solaris Endovascular
Research & Knowledge
Solaris Endovascular shared the 6-month results of the DEScover Phase II trial of Solaris DE on Saturday.
Reported by Matthew Head